Already a member? Sign in
Zolmitriptan is used to treat the symptoms of migraine headache. It is in a class of medications called selective serotonin (5-HT) receptor agonists. It does not prevent migraine headaches. It comes in oral tablet form or as a nasal spray.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Migraine | 89 | 17 |
|
|
|
|
|
| Migraine headaches | 55 | 12 |
|
|
|
||
| Migraine with aura | 5 | 0 | |||||
| Atypical Migraine | 5 | 2 |
|
|
|||
| Other | 5 | 3 |
|
|
|
||
| Headaches | 3 | 2 |
|
See all 94 patients currently taking Zolmitriptan
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Zolmitriptan
| Face Tingling | 3 | |
|---|---|---|
| Chest pain | 2 | |
| Drowsiness | 2 | |
| Dizziness | 2 | |
| Numbness in right side | 1 | |
| Poor circulation in hands and feet | 1 | |
| See all 12 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Zolmitriptan. See all 11 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 35 | ||
| Doctor's advice | 14 | ||
| Side effects too severe | 12 | ||
| Other | 9 | ||
| Expense | 4 | ||
| Course of treatment ended | 3 | ||
| Personal research | 2 | ||
| Change in health plan coverage | 2 | ||
| Not indicated | 1 |
Adherence
Taking treatment as prescribed
Adherence of Zolmitriptan
Always |
25 | 76% |
|
|---|---|---|---|
Usually |
5 | 15% |
|
Sometimes |
3 | 9% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Zolmitriptan
Very |
0 | 0% |
|
|---|---|---|---|
Somewhat |
2 | 6% |
|
A little |
2 | 6% |
|
Not at all |
29 | 88% |
|
Cost
Paid out of pocket
Cost of Zolmitriptan
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
1 | 6% |
|
$25-49 |
3 | 18% |
|
< $25 |
12 | 71% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on May 27, 2012.